Investor Presentaiton
ersonal use only
11
Maintaining a strong focus on growth drivers through COVID
Despite the COVID-19 pandemic stalling lab roll out plans during 2020, Imricor maintained clear
focus on progressing initiatives across the business to support future growth
✓ Launched online training and education seminars
✓ Contracted nine sites and significantly grew the pipeline of potential new sites
✓ Signed a sales agreement with Philips to sell Imricor's capital equipment as part of Phillips iCMR
implementation package & working towards a similar agreement with Siemens
Signed a master purchasing agreement with Sana GPO, streamlining access to -80 sites performing cardiac
ablations
✓ Awarded a contract from the US National Institutes of Health (NIH) to develop an MRI compatible myocardial
biopsy system
✓ Entered into agreements with Optoacoustics & Osypka to provide a sales channel for the supply of products to
Imricor's customers for iCMR ablation procedures
✓ Progressed strategy around regulatory approvals to expand indications and geographic reach
✓ Continued to expand the workforce to ensure capacity and capability to deliver Imricor's growth strategy
Imricor FY20 Investor Presentation, February 2021View entire presentation